2016 ASH Annual Meeting

Follow our coverage of the 2016 ASH Annual Meeting.

Learn more

Who’s In and Who’s Out?

This feature focuses on the challenges of designing a clinical trial that is internally and externally valid.

Learn more

Charles S. Abrams, MD

Charles S. Abrams, MD, talks about the value of working as a team and getting out of one’s comfort zone.

Learn more

Written in Blood

A study finds sickle cell trait carrier status is not associated with baseline or long-term changes in cardiopulmonary fitness.

Learn more

2016 ASH Mentor Awards

A discussion with Ralph Nachman, MD, the winner of the 2016 ASH Basic Science Mentor Award.

Learn more
Advertisement

New Exclusive Videos

View all Exclusive Videos

  • So You Say You Want To Be A Clinical Researcher?

    Perhaps you’ve just finished your hematology/oncology fellowship a year or two ago. Or you’re still a fellow and, having completed that intensive first year of inpatient consults and the speed dating outpatient rotations in different specialty clinics, you’ve just woken up to the realization that you have to apply for jobs in a year. Or […]

  • On Eating Bone Marrow

    The first time I ate bone marrow was, fittingly, shortly after I spoke on marrow failure at a conference in Milan, where osso bucco with saffron risotto is a local specialty. The tiny, back-alley trattoria where I could afford dinner on a hematology fellow’s salary was praised in a guidebook written by public television’s European […]

  • A Primer on Email Etiquette

    Every day, more than 200 billion emails are sent and received, for an average of 122 emails sent and received, per user, in a business setting.1 Having just returned from a week of vacation, we believe that approximately all of those 200 billion emails were waiting for us in our inboxes. As we spend increasing […]

  • The Decline and Fall of Cytotoxic Chemotherapy

    Here, Dr. Stewart gives his take on whether cytotoxic chemotherapy should be declared a thing of the past. As ward rounds ended last Saturday, a slow-brew blend of my own clinical experience and what I have seen as reproducibly disappointing outcomes coalesced in my strong desire to speed the delivery of cytotoxic chemotherapy to the waste heap of […]

View all Editor`s Corner
  • To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

    Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug levels a challenge. Researchers are now investigating whether adding genomic information to dosing algorithms could better identify the optimal starting dose for patients new to warfarin, minimize variability in drug response, […]

  • Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

    Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For nearly 10 years, the standard of care for the treatment of AHA was either recombinant factor VIIa (rFVIIa) or FVIII inhibitor bypass activity (FEIBA), known as a “bypassing agent” because it […]

  • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

    Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of […]

  • Optimal Timing of Transplant in Myeloma

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

View all Drawing First Blood
  • CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

    In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician reimbursements for prescription drugs.1 According to CMS, the rule will test different physician incentives that would, in theory, encourage the prescription of the most effective drugs and reward positive patient outcomes. […]

  • Choosing Wisely Across the Internal Medicine Spectrum: Which Recommendations Should Hematologists Pay Attention To?

    In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies at the 2015 annual meeting. Choosing Wisely encourages clinicians and patients to engage in conversations to reduce waste and overuse in health care. […]

  • New Medicare Care Choices Model Seeks to Expand Access to Palliative Care

    On July 20, 2015, the Centers for Medicare& Medicaid Services (CMS) announced the 141 hospices that have been selected to participate in the new Medicare Care Choices Model (MCCM), a pilot program designed to expand patients’ access to palliative and hospice care.1 The new model provides clinicians, beneficiaries, and their families with greater flexibility in deciding between hospice care and active […]

  • ICD-10: Ready or Not!

    After two one-year reprieves, it’s finally here: The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Nationwide, on October 1, 2015, all health-care business transactions in the United States converted to ICD-10 from the previous version of the ICD (ICD-9). If they did not convert, claims and electronic transactions will be rejected. The ICD-9 […]

View all Practice Update